Do not use in horses intended for human consumption.

Do not administer to animals with renal, hepatic or cardiac disorders, where there is the possibility of gastro-intestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product.

Avoid use in dehydrated, hypovolemic or hypotensive animals as there is an increased risk of renal failure.

After continuous use, or when used at high doses, gastro-intestinal changes may occur. Occasionally, blood dyscrasias and renal alterations may be found, especially in animals with restricted access to drinking water.

Use in very young (less than 12 weeks) or aged animals may involve additional risk. Ensure accurate assessment of dose to body weight and closely monitor clinical response.

Studies have not been carried out in the horse to establish safe use during pregnancy and lactation.

All NSAIDs can inhibit phagocytosis and hence, during treatment of inflammatory conditions associated with bacterial infections, appropriate antimicrobial treatment should also be used.

In case of accidental continuous overdose, the following symptoms may occur: thirst, depression, anorexia and weight loss; gastro intestinal disorders (irritation, ulcers, diarrhoea and faecal blood); altered blood profiles and haemorrhages; hypoproteinaemia with ventral oedema causing hemoconcentration, hypovolemic shock and circulatory collapse; renal failure and fluid retention.

If signs of intolerance appear, discontinue administration and apply symptomatic treatment.

A slow intravenous infusion of a solution of sodium bicarbonate, which leads to urine alkalinisation, increases the clearance of the product..

Suxibuzone and its metabolites may be highly bound to plasma proteins and compete with other highly bound drugs eg. sulphonamide, warfarin. Concurrent administration of other highly bound drugs will lead to an increase of non-bound plasma concentrations, which may lead to toxic effects. Drug compatability must be closely monitored when adjunctive therapy is required.

Do not administer concurrently with other NSAIDs or within 24 hours of other NSAIDs.

Concurrent administration of potentially nephrotoxic drugs should be avoided.

Wear suitable gloves. Wash hands after use. Use in a well-ventilated area. Avoid inhaling any dust when opening sachet and mixing with feed. In case of accidental contact with eyes, wash immediately with plenty of clean water. In case of accidental ingestion, seek medical advice immediately.